365NEWSX
365NEWSX
Subscribe

Welcome

Booster dose neutralizes COVID-19 Omicron variant: Study - ANI News

Booster dose neutralizes COVID-19 Omicron variant: Study - ANI News

Booster dose neutralizes COVID-19 Omicron variant: Study - ANI News
Jan 16, 2022 1 min, 25 secs

Washington [US], January 16 (ANI): An international team of researchers recently studied the sensitivity of Omicron to antibodies compared with the currently dominant Delta variant.

The new COVID-19 Omicron variant is more transmissible than the Delta variant.

In a new study supported by the European Union's Health Emergency Preparedness and Response Authority (HERA), scientists from the Institut Pasteur and the Vaccine Research Institute, in collaboration with KU Leuven (Leuven, Belgium), Orleans Regional Hospital, Hospital Europeen Georges Pompidou (AP-HP) and Inserm, studied the sensitivity of Omicron to antibodies compared with the currently dominant Delta variant.

The scientists from KU Leuven isolated the Omicron variant of SARS-CoV-2 from a nasal sample of a 32-year-old woman who developed moderate COVID-19 a few days after returning from Egypt.

The isolated virus was immediately sent to scientists at the Institut Pasteur, where therapeutic monoclonal antibodies and serum samples from people who had been vaccinated or previously exposed to SARS-CoV-2 were used to study the sensitivity of the Omicron variant.

Six antibodies lost all antiviral activity, and the other three were 3 to 80 times less effective against Omicron than against Delta.

The Tixagevimab/Cilgavimab combination (developed by AstraZeneca under the name Evusheld) was 80 times less effective against Omicron than against Delta.

Most of the therapeutic monoclonal antibodies currently available against SARS-CoV-2 are inactive," commented Olivier Schwartz, co-last author of the study and Head of the Virus and Immunity Unit at the Institut Pasteur.

Five to 31 times more antibodies were nevertheless required to neutralize Omicron, compared with Delta, in cell culture assays.

"This study shows that the Omicron variant hampers the effectiveness of vaccines and monoclonal antibodies, but it also demonstrates the ability of European scientists to work together to identify challenges and potential solutions.

Summarized by 365NEWSX ROBOTS

RECENT NEWS

SUBSCRIBE

Get monthly updates and free resources.

CONNECT WITH US

© Copyright 2024 365NEWSX - All RIGHTS RESERVED